Previous close | 0.8611 |
Open | 0.9090 |
Bid | 0.9400 x 1000 |
Ask | 0.9700 x 1100 |
Day's range | 0.8899 - 1.0000 |
52-week range | 0.7400 - 2.5450 |
Volume | |
Avg. volume | 29,940,570 |
Market cap | 2.104B |
Beta (5Y monthly) | 1.36 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4600 |
Earnings date | 01 Mar 2024 - 05 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.92 |
Key Insights Significantly high institutional ownership implies Ginkgo Bioworks Holdings' stock price is sensitive to...
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, beginning at 5:30 p.m. ET.
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the nomination of Myrtle Potter and Ross Fubini for election as independent directors at Ginkgo's upcoming annual meeting, scheduled to be held on June 13, 2024.